MEDIA

Press Releases

Select Year

Revance Therapeutics (RVNC) Announces FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines)

Revance Receives FDA Acceptance of BLA Resubmission for DaxiboutlinumtoxinA for Glabellar Lines

FDA Accepts Revance Application for Its Injection To Treat Frown Lines

How Beauty Innovations Are Approved Here and Abroad – Plus the Global Game Changers Doctors are Buzzing About